Woodcock Plans to Revamp NDA Program Infrastructure
CDER plans to start using a new informatics platform for new drug approvals in October, following the processes already in place for generic drug reviews, says CDER Director Janet Woodcock.…
CDER plans to start using a new informatics platform for new drug approvals in October, following the processes already in place for generic drug reviews, says CDER Director Janet Woodcock.…
Inovar received a Form 483 for failing to provide a product certification, evaluate complaints, and other observations. Source: The GMP Letter
Flotec was hit with a Form 483 for inadequate reviews of nonconforming products, poorly documented corrective action procedures, and inadequate complaint reviews. Source: The GMP Letter
India has finalized new regulations that separate out devices for the first time from broader drug regulations. Source: The GMP Letter
Germany’s Biotronik received a warning letter for inadequate process validation procedures, supplier selection procedures, and other violations. Source: The GMP Letter
Korea-based Neo Vision received a warning letter for failing to establish proper design controls, monitor production processes, maintain device history records, and other violations. Source: The GMP Letter
Heater cooler units used in cardiopulmonary bypass and extracorporeal membrane oxygenation can generate potentially infectious aerosols containing a range of harmful bacteria, some of which can be fatal, according to…
The FDA slapped medical device manufacturer XZeal Technologies with a Form 483, citing issues with reporting procedures and design validation. Source: The GMP Letter
A manufacturing defect in MicroPort Orthopedics’ Biolox Forte 36 mm Alumina ceramic heads may cause surgical complications, according to Australia’s Therapeutic Goods Administration. Source: The GMP Letter
The FDA sent Canada-based Savaria Concord Lifts a warning letter citing twelve violations regarding corrective and preventive actions (CAPAs), complaint evaluations, software validation, and other areas. Source: The GMP Letter